Is acute myeloid leukemia treatment possible without transplant?

Yes, for favorable-risk AML or elderly patients unfit for transplant, chemotherapy with or without targeted therapy can achieve remission.

What is the AML transplant success rate?

With matched donors and early transplant during first remission, success rates range between 50%–70% depending on age, risk factors, and MRD status.

How long does acute myeloid leukemia (AML) treatment take?

Induction chemotherapy usually takes 4–6 weeks. Consolidation or transplant requires another 4–8 weeks. Post-transplant recovery may last several months.

How is acute myeloid leukemia (AML) different from chronic myeloid leukemia (CML)?

AML is acute and aggressive, requiring immediate intensive therapy. CML is a chronic disease often managed long-term with oral targeted drugs like imatinib

What is acute myeloid leukemia (AML) remission treatment?

It includes post-chemotherapy or post-transplant follow-up, MRD monitoring, immunosuppression tapering, and infection prevention to avoid relapse.

Is acute myeloid leukemia (AML) common in India?

Yes, AML is one of the most common acute leukemias in adults, and its incidence is rising in urban populations.

Can children get AML?

Yes. AML in children and adolescents requires pediatric-specific treatment protocols and is managed by our expert pediatric oncology team.

What is acute lymphocytic leukemia (ALL)?

ALL is a fast-growing cancer of the bone marrow and blood that affects lymphoid precursor cells. It occurs in both children and adults and requires immediate, specialized treatment.

What are the early symptoms of Acute Lymphocytic Leukemia (ALL)

Common symptoms include fatigue, infections, bruising or bleeding, bone pain, and swollen lymph nodes. Prompt diagnosis is essential.

How is ALL diagnosed at BMT Next?

We use CBC, bone marrow biopsy, flow cytometry, cytogenetics (e.g., BCR-ABL1), MRD testing, and next-generation sequencing to confirm the diagnosis and subtype.

What is the success rate for pediatric Acute Lymphocytic Leukemia (ALL) at BMT Next?

In standard-risk pediatric ALL, our survival rates exceed 94%, aligning with top international benchmarks.

What is the role of bone marrow transplant in ALL?

BMT is offered to patients with high-risk features, poor response to induction therapy, relapsed disease, or specific cytogenetic abnormalities like Ph+ ALL.

Can adults with ALL also be treated at BMT Next?

Yes. We treat adult ALL using age-adapted protocols and offer reduced-intensity transplant regimens when needed.

What targeted therapies do you offer for relapsed or refractory Acute Lymphocytic Leukemia (ALL)?

We provide access to Blinatumomab (BiTE), Inotuzumab ozogamicin, and TKIs for Ph+ ALL. CAR-T therapy is coordinated with leading centers in India.

How does BMT Next support international patients from Mauritius or Africa?

We offer virtual consultations, visa and travel assistance, multilingual care coordination, and continuity of treatment between India and Mauritius.

Is CAR-T cell therapy available for Acute Lymphocytic Leukemia (ALL)at BMT Next?

Yes. We collaborate with accredited CAR-T therapy partners to treat CD19+ relapsed/refractory ALL cases.

How is MRD testing used to guide treatment?

MRD (Minimal Residual Disease) testing after induction and consolidation phases helps assess treatment effectiveness and guides the need for BMT.

What are the side effects of chemotherapy for Acute Lymphocytic Leukemia (ALL)?

Side effects include neutropenia, infections, nausea, hair loss, and fatigue. We manage toxicity through supportive care and growth factor use.

Do you provide fertility preservation for young ALL patients?

Yes. We offer fertility counseling and options like sperm banking and ovarian tissue preservation before intensive chemotherapy or transplant.

How long is treatment for acute lymphocytic leukemia?

Pediatric ALL treatment typically lasts 2–3 years. Adult protocols are shorter but may include transplant or advanced therapies.

What makes BMT Next different from other leukemia centers?

We provide MRD-guided treatment, access to immunotherapy and transplant, global referrals, and unmatched survival outcomes in India.

How can I book a second opinion at BMT Next?

You can request a virtual or in-person second opinion by sharing your reports through our patient portal or contacting our coordination team directly.

Why is BMT Next considered the best center for acute lymphocytic leukemia (ALL) treatment in Gurgaon (Gurugram)?

BMT Next in Gurgaon is equipped with advanced genomic testing, CAR-T therapy access, expert-led transplant services, and participation in international clinical trials. It offers personalized care for both pediatric and adult ALL patients, combining technology, experience, and outcomes that meet global standards.

What is multiple myeloma and how is it different from other blood cancers?

Multiple myeloma is considered a cancer of plasma cells, a type of white blood cell that helps fight infection. Unlike leukemia or lymphoma, it majorly affects the bone marrow and skeletal system.

What are the early signs of multiple myeloma?

Early signs include persistent bone pain, frequent infections, unexplained fatigue, anemia, kidney dysfunction, and high calcium levels.

How is multiple myeloma diagnosed at BMT Next?

We use a combination of blood tests (SPEP, IFE, FLC), bone marrow biopsy, PET-CT or MRI, and FISH cytogenetic studies to confirm diagnosis and risk stratify the disease.

What is the role of FISH cytogenetics in myeloma diagnosis?

FISH identifies genetic abnormalities like del(17p), t(4;14), or 1q gain, which help us predict prognosis and customize treatment.

Is bone marrow transplant mandatory for all myeloma patients?

No. Autologous stem cell transplant (ASCT) is recommended for eligible patients to prolong remission, but alternatives exist for transplant-ineligible individuals.

What is CAR-T therapy and is it available at BMT Next?

CAR-T therapy involves genetically modifying a patient’s own T-cells to fight myeloma. It is available through clinical access programs at BMT Next.

. What are the treatment options for relapsed or refractory myeloma?

Options include immunomodulators like Pomalidomide, monoclonal antibodies like Daratumumab, BiTE therapies, and CAR-T cells.

How does BMT Next monitor treatment response?

We use MRD (minimal residual disease) testing via flow cytometry or NGS to monitor the depth of remission after treatment.

Are there different types of multiple myeloma?

Yes, including smoldering myeloma (asymptomatic), active myeloma (requiring treatment), and relapsed/refractory myeloma.

What support services are offered at BMT Next for myeloma patients?

Patients receive nutritional counseling, pain management, physiotherapy, renal care, and emotional wellness support throughout treatment.

What makes BMT Next the best center for multiple myeloma treatment in India?

BMT Next offers the best multiple myeloma treatment in India through its expert-led centers in Gurgaon, Hisar, Faridabad, and Mauritius. Our strength lies in bone marrow transplant excellence, MRD-based treatment, next-level FISH cytogenetics, and access to CAR-T and BiTE therapy. Patients across North India and internationally choose BMT Next for high-quality, affordable, and personalized plasma cell cancer treatment.

How can patients from Mauritius access myeloma care at BMT Next?

Our international patient desk helps with appointment scheduling, visa support, travel coordination, and follow-up teleconsultation.

How often should follow-up occur after myeloma treatment?

Follow-up is typically every 3–6 months with blood tests, MRD monitoring, and imaging when needed.

What is lenalidomide maintenance and why is it important?

Lenalidomide is used after transplant or initial therapy to maintain remission and delay progression. It is a cornerstone of long-term management.

Are affordable treatment packages available for myeloma at BMT Next?

Yes. We offer cost-effective care across Hisar, Faridabad, and Gurgaon with insurance, CGHS, and EMI support.

What is the success rate of bone marrow transplant in India?

At leading centers like BMT Next, the success rate for bone marrow transplant ranges between 70% to 90%, depending on the disease type, patient condition, and transplant match. Conditions like thalassemia, aplastic anemia, and acute leukemia show high cure rates when treated early.

How much does a bone marrow transplant cost in India?

The cost varies between ₹8 to ₹25 lakhs, based on the type of transplant. Autologous BMTs are usually less expensive than allogeneic or haploidentical transplants. BMT Next offers transparent packages in Gurgaon, Faridabad, Hisar, and Mauritius with financial counseling support.

How long does a bone marrow transplant take?

The full procedure—including pre-evaluation, transplant, and initial recovery—typically takes 4 to 6 weeks. Post-discharge monitoring continues for 6 to 12 months depending on the patient’s immune recovery.

Who can be a donor for bone marrow transplant?

Donors may be siblings, matched unrelated individuals, or half-matched (haploidentical) family members. At BMT Next, we conduct HLA typing and also work with global donor registries if a family match isn’t available

Is bone marrow transplant painful?

The transplant itself is not painful. It’s a stem cell infusion given through a vein, very similar to a blood transfusion. Pre-transplant chemotherapy may cause side effects, which are managed by our transplant care team.

Which diseases are treated with bone marrow transplant?

We treat leukemia, lymphoma, multiple myeloma, aplastic anemia, thalassemia, sickle cell anemia, MDS, and rare immunodeficiency syndromes. BMT Next specializes in both adult and pediatric BMTs across all these conditions.

Can international patients get bone marrow transplant in India?

Yes. Through our Mauritius center, international patients from Africa, the Middle East, and Indian Ocean islands can access India’s best BMT care with visa assistance, translator support, and telemedicine follow-up.

What are the risks of bone marrow transplant?

Like any major medical procedure, BMT carries risks such as infection, graft-versus-host disease (GVHD), and delayed engraftment. However, at BMT Next, we use strict infection control, ICU monitoring, and early GVHD management to minimize complications.

Why is BMT Next considered among the best bone marrow transplant centers in India?

With over 3,000+ transplants performed, MRD-guided therapy, internationally trained specialists, and a strong presence in Gurgaon, Faridabad, Hisar, and Mauritius, BMT Next combines experience with accessibility and affordability.

How soon should I consult for a bone marrow transplant?

Early consultation is critical—especially for high-risk leukemia, aplastic anemia, or relapsed cancers. Delays can affect survival. Contact BMT Next today to schedule a transplant evaluation at your nearest center.

Doctor Profile

Dr. umesh Kumar

Bone Marrow Transplant , Cancer Care / Hematology, Oncology

Attending consultant – Hematology-oncology and bone marrow transplant Unit Marengo Asia Hospital Gurugram and Faridabad

Qualifications

MD (Physician) from International Higher School of Medicine, Bishkek
Diploma in Hematology, Israel
Fellowship in Hemato_Oncology level-1 from Dr. M.G.R. Medical University, Tamilnadu.

Areas of Expertise

Have experience with expert clinician, around 100 in Bone Marrow Transplant / Stem Cell Transplants including Autologous and Allogenic transplants

Experience in managing various disorders (Both Adult and Pediatric) like:

Acute Leukemia (AML & ALL)
Chronic Leukemia (CML & CLL)
Lymphoma (Hodgkin’s & Non – Hodgkin’s)
Plasma cell dyscrasia (Multiple Myeloma & others)
Myelodysplastic Syndrome (MDS)
Myeloproliferative neoplasm (polycythemia
thrombocytosis, myelofibrosis ) Non- Malligant / Bengin Hematology
Experience in Managing Following Disorders (both Adult & Paediatric)
Anemia (Hemolytic, Aplastic , Nutritional Anemia & others)
Thrombocytopenia (ITP & Others)
Neutropenia
Eosinophilia
Pancytopenia
Thalassemia & Hemoglobinopathies
Hemophilia & other Coagulation Disorders
Consultative Hematology

Overview :

Dr. Umesh Kumar working in department of Hematology – Oncology and Bone marrow transplant unit in Marengo Asia Hospital, Gurugram & Faridabad.
Over seven years of experience in various reputed hospitals
Senior resident in Marengo Asia Hospital, Gurugram for 2 years
1.6 years’ experience as a resident medical officer in park hospital, Panipat.
2 years’ experience in medical faculty in Sonia Nursing Home, Rewari.
1.6year’s experience as resident in hematology and bone marrow transplant department in Fortis Memorial Research Institute, Gurugram (HR).
6 month’s work in SNCU/NICU & PICU ward as a medical officer, Civil Hospital, Rewari.

Awards and ACCOLADES

Diploma in Hematology completion of a course approved by IMA for CME in Israel (March /2025)
Certificate awards for completion of fellowship in Hemato_Oncology level-1 (June /2023).
Certificate awards for completion of a course of (FIMNCI) (January /2023).
Certificate awards for completion of ICH GOOD clinical practice E6 R-2 (JAN/2024)
Certificate awards for ACLS provider certifications by NHCPS (JAN/2024)
Certificate awards for investigator site Personnel ICH GCP training (Feb/2024)
Certificate awardrs for completion of a course of Russian language (June /2017)

MEMBERSHIP

Life Member Of Indian Medical Association, Gurugram, Haryana
ASH Hematology (American Society of Hematology)
E-BMT

Doctor Profile

Dr. umesh Kumar

Attending consultant – Hematology-oncology and bone marrow transplant Unit Marengo Asia Hospital Gurugram and Faridabad

Qualifications

Areas of Expertise

Experience in managing various disorders (Both Adult and Pediatric) like:

Overview :

Awards and ACCOLADES

MEMBERSHIP

Useful Links

Work Hours

Call us

Email